IRCT20230414057906N1尚未招募2 期
Efficacy and safetyof Lutetim-177-PSMA-617 therapy in paitents with metastatic prostate cancer after radical prostatectomyand bilateral orchitectomy
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 85 years（—）
- 性别
- Male
入选标准
- •Men with metastatic prostate cancer after radical prostatectomy and bilateral orchitectomy
- •68Ga-PSMA-PET/CT positive scan
- •Having willingness to participate in this study
排除标准
- •Creatinine >=2 mg/dl
- •Obstructive DTPA SCAN
- •Previous history of chemotherapy/radiotherapy for prostate cancer
- •PLAT=75000
- •ALT/AST >5 times of upper normal limit for those with liver metastasis or <2 times for those without liver metastasis.
- •Patients with life expectancy <12 weeks
研究者
相似试验
进行中（未招募）
2 期
utetium PSMA versus Docetaxel in metastatic castration resistant prostate cancerCTRI/2019/12/022282Postgraduate Institute of Medical Education and Research40
尚未招募
2 期
Effect of Lu177-dotatate in meningiomaMeningioma.Malignant neoplasm of meninges, unspecifiedC70.9IRCT20190623043986N1Shiraz University of Medical Sciences10
进行中（未招募）
不适用
Efficacy and safety of Levetiracetam treatment in patients suffering from Restless Legs SyndromeEficacia y seguridad de un tratamiento con levetiracetam en pacientes con síndrome idiopático de piernas inquietasRestless legs syndrome (RLS)EUCTR2005-001516-41-ESClínica Plató Fundació Privada12
招募中
1 期
Study to evaluate the effect of Luspatercept on transfusion independence of red blood cells (lack of transfusions for 8 consecutive weeks within the first 24 weeks) in subjects with MDS with del (5q) with very low risk, low risk, intermediatedel IPSS-R index and and <5% blasts, resistant / refractory / intolerant to Lenalidomide and dependent on red blood cell transfusions.Anemia due to MDS with del5q with IPSS-R very low, low, or intermediate risk MDS and a bone marrow blast count of < 5% , Refractory or intolerant to, or ineligible for, prior ESA treatment and for prior lenalidomide treatment and who require RBC transfusions.MedDRA version: 20.0Level: LLTClassification code 10028532Term: MyelodysplasiaSystem Organ Class: 100000004864EUCTR2021-001538-20-ITASSOCIAZIONE QOL-ONE22
进行中（未招募）
1 期
Clinical-imaging study assessing the value of biological parameters obtained through multimodality molecular and functional imaging (differences in 68Ga-octreotate and 18FDG uptake, changes in diffusion weighted magnetic resonance imaging and 177Lu-octreotate dosimetry) for the prediction of treatment outcome in advanced refractory gastroenteropancreatic neuroendocrine tumors.Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative intent.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2012-003666-41-BEJules Bordet Institute52